NewsBenzingaDenali Therapeutics prevede vendite nel quarto trimestre di 30,000 milioni di dollari-32,000 milioni di dollari rispetto ai 22,659 milioni di dollari stimati Denali Therapeutics prevede vendite nel quarto trimestre di 30,000 milioni di dollari-32,000 milioni di dollari rispetto ai 22,659 milioni di dollari stimati Benzinga 2026.11.03 22:35 (GMT+0) Open on Benzinga Other news Abraxas Capital Moves $109 Million USDC to Binance After Closing Its ~$200 Million Hyperliquid Positions Ledger Hardware Wallet Tampering Spreads to Dubai as Two Users Lose About $604K Nvidia Board Has No Plans to Reinstate Jensen Huang AMD completes acquisition of AI inference chip company Taalas HUYA Inc. (HUYA) Q3 2026 Earnings Call Transcript Key Overnight and Morning News (Nov 17 – Nov 18)
Abraxas Capital Moves $109 Million USDC to Binance After Closing Its ~$200 Million Hyperliquid Positions